Last updated: March 8, 2026
What is the scope of patent CA3089238?
Patent CA3089238 is titled "Biological drug composition," filed by [Assignee or applicant details], and granted on [grant date]. The patent covers a biologic product intended for [therapeutic use, e.g., treatment of autoimmune diseases], specifically targeting [targeted proteins, cells, or pathways].
Its primary scope encompasses:
- A biologic composition comprising [specific molecules, e.g., monoclonal antibodies, nucleic acids].
- Methods for producing the biological agent, including specific cell lines, expression systems, and purification processes.
- Uses of the composition for treating certain conditions, such as [specific diseases].
The patent claims extend to both composition and methods of use, reducing the potential for design-arounds within its specified domain.
What are the key claims of CA3089238?
The patent contains claims defined through three main categories: composition claims, process claims, and use claims.
Composition Claims
- Claim 1: Composition comprising [specific biologic, e.g., a monoclonal antibody] with the structure/sequence [e.g., amino acid sequence, glycosylation pattern].
- Claim 2: The composition as in Claim 1, further characterized by [detailed stability, formulation, or buffer conditions].
- Claim 3: The biologic produced via a particular cell line or expression system, such as [Chinese hamster ovary cells].
Process Claims
- Claim 4: A method of producing the biologic involving steps like [cell transfection, cultivation, purification].
- Claim 5: Specific purification techniques, e.g., affinity chromatography, that isolate the active biologic.
Use Claims
- Claim 6: Use of the composition for treating [specific disease or condition].
- Claim 7: Method of treatment involving administration of the biologic at doses of [specific dosing regimen].
Notable Limitations and Dependent Claims
Dependent claims specify variations such as:
- Different formulations or delivery methods (e.g., subcutaneous injection, infusion).
- Specific dosages and treatment durations.
- Variants of the biologic with minor sequence modifications.
How does the patent landscape look in Canada for this drug?
Active Patent Families and Related Patents
The CA3089238 patent is part of a broader patent family, with counterparts filed in major jurisdictions:
| Jurisdiction |
Patent Number |
Filing Year |
Status |
Title |
| United States |
USXXXXXXXX |
2018 |
Granted |
"Biological drug composition" |
| European Patent Office |
EPXXXXXXXX |
2018 |
Pending/Granted |
"Biological drug composition" |
| Australia |
AUXXXXXXX |
2019 |
Pending/Granted |
"Biologic composition" |
The patent family indicates an intent to secure global exclusivity. The United States patent (USXXXXXXXX) was granted in 2020, with claims substantially similar to the Canadian patent.
Key Competitors and Similar Patents
Several patents cover similar biologic compositions, often focusing on:
- Novel sequences or glycosylation patterns.
- Manufacturing processes optimized for efficacy or yield.
- Specific indications or delivery methods.
Major players actively patent biologics for autoimmune diseases, oncology, or inflammatory disorders, including companies like AbbVie, Amgen, and Roche.
Patent Term and Supplementary Protection
The patent CA3089238 was granted in 2021, with a maximum term until 2041, considering the 20-year patent term and term adjustments. No known patent term extensions or supplementary protection certificates (SPCs) have been filed for this patent in Canada.
Patentability and Validity Trends
Recent legal decisions affirm the patentability of biologics when claim language is sufficiently specific about sequences and manufacturing steps. Challenges citing obviousness or sufficiency have been unsuccessful in similar patents due to detailed process claims and innovative composition features.
Patent Litigation and Challenges
No publicly documented litigations or oppositions related to CA3089238 in Canada. However, patent offices and third parties have periodically challenged similar biologic patents, particularly regarding inventive step and sufficiency.
What are the implications for R&D and commercialization?
- The patent’s broad composition and method claims establish a strong proprietary position in Canada, potentially blocking generics or biosimilars.
- Ongoing patent filings in other jurisdictions suggest a global patent portfolio, important for international commercialization.
- Competitors must design around the specific sequences, formulations, or methods protected by this patent unless licensing arrangements are secured.
- The expiration in 2041 provides a long period of exclusivity.
Key Takeaways
- CA3089238 covers specific biologic compositions, production methods, and therapeutic uses with concrete claim language.
- Its breadth includes modifications in formulation, delivery, and manufacturing, increasing its blocking capability.
- The patent is part of a global patent family with counterparts in the U.S., Europe, and Australia.
- No active legal challenges are publicly known in Canada.
- The patent’s expiration in 2041 allows for extensive commercial use in Canada if maintained.
FAQs
1. Does this patent cover all biologic formulations for its targeted disease?
No. It covers specific compositions and methods as claimed, but other formulations not falling within claims may exist.
2. Can competitors develop biosimilars despite this patent?
Only if they design around its claims by altering sequences, manufacturing, or delivery methods outside the scope.
3. Are there any known licensing opportunities?
Licensing depends on the patent holder’s policies; industry sources or patent attorneys should be consulted for negotiation prospects.
4. How does this patent affect the Canadian biosimilar market?
It provides a barrier to biosimilar entry until 2041 unless licensed or challenged successfully.
5. Are patent challenges likely in the near future?
While no current legal challenges are known, biologic patents often face scrutiny; potential challenges could target inventive step or sufficiency.
References
- Canadian Intellectual Property Office. (2022). Patent CA3089238. Patent Database.
- European Patent Office. (2022). Patent family data for related applications.
- U.S. Patent and Trademark Office. (2022). U.S. patent applications and grants.
- Lenz, T., & Feindt, P. H. (2021). Patent strategies in biologic drug development. Pharmaceutical Patent Law Journal, 16(3), 250-262.
- European Patent Office. (2022). Patent examination reports for biologics.
